The price of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares last traded on Wall Street fell -4.25% to $0.23.
Based on available information, 9 analysts follow Atara Biotherapeutics Inc (NASDAQ:ATRA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $0.50, we find $4.80. Given the previous closing price of $0.24, this indicates a potential upside of 1900.0 percent. ATRA stock price is now -84.19% away from the 50-day moving average and -90.26% away from the 200-day moving average. The market capitalization of the company currently stands at $23.42M.
Among analysts, 4 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $10.53 as their price target over the next twelve months.
With the price target reduced from $31 to $1, Mizuho Downgraded its rating from Buy to Neutral for Atara Biotherapeutics Inc (NASDAQ: ATRA).
In other news, Touchon Pascal, President and CEO sold 30,766 shares of the company’s stock on Aug 16. The stock was sold for $50,835 at an average price of $1.65. Upon completion of the transaction, the President and CEO now directly owns 675,905 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 16, EVP, Chief Sci. & Tech Officer Nguyen AnhCo sold 15,126 shares of the business’s stock. A total of $24,997 was realized by selling the stock at an average price of $1.65. This leaves the insider owning 285,999 shares of the company worth $65779.77. Insiders disposed of 216,605 shares of company stock worth roughly $49819.15 over the past 1 year. A total of 5.19% of the company’s stock is owned by insiders.
A candlestick chart of Atara Biotherapeutics Inc (NASDAQ: ATRA) showed a price of $0.2641 on Friday morning. During the past 12 months, Atara Biotherapeutics Inc has had a low of $0.23 and a high of $5.64. The fifty day moving average price for ATRA is $1.4290 and a two-hundred day moving average price translates $2.3347 for the stock.
The latest earnings results from Atara Biotherapeutics Inc (NASDAQ: ATRA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.68, missing analysts’ expectations of -$0.67 by -0.01. This compares to -$0.82 EPS in the same period last year. The net profit margin was -6390.31% and return on equity was -425.97% for ATRA. The company reported revenue of $2.14 million for the quarter, compared to $4.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -52.05 percent. For the current quarter, analysts expect ATRA to generate $4.76M in revenue.
Atara Biotherapeutics Inc(ATRA) Company Profile
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
